|
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. |
| |
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca/Daiichi Sankyo; Athenex; Ayala Pharmaceuticals; bioTheranostics; Immunomedics |
Speakers' Bureau - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Honoraria - Athenex; bioTheranostics; natera; OncoCyte |
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax |
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies |
| |
|
Consulting or Advisory Role - Agendia |
Research Funding - Agendia |
| |
|
Employment - Aptitude Health; Integra LifeSciences (I) |
Leadership - Integra LifeSciences (I) |
Stock and Other Ownership Interests - Aptitude Health; Integra LifeSciences (I) |
|
Consulting or Advisory Role - ImpediMed; Prelude Therapeutics |
Research Funding - Agendia; Exact Sciences; Prelude Therapeutics |
Travel, Accommodations, Expenses - Targeted Medical Education, Inc. |
| |
|
|
Leadership - Targeted Medical Education, Inc. |
Stock and Other Ownership Interests - InVitae; Targeted Medical Education, Inc. |
Honoraria - Castle Biosciences |
Research Funding - InVitae |
(OPTIONAL) Uncompensated Relationships - Medneon |
| |
|
Honoraria - Agendia; Breast Cancer Index; Guardant Health; Immunomedics; Seagen |
Speakers' Bureau - Lilly; Novartis |
Travel, Accommodations, Expenses - Lilly; Novartis |
| |
Rakhshanda Layeequr Rahman |
Honoraria - MOLLI Surgical |
| |
Nathalie MCDOWELL Johnson |
Research Funding - Agendia |
| |
|
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen |
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst) |
Expert Testimony - Pfizer |
| |
|
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics |
Speakers' Bureau - Seattle Genetics/Astellas |
Research Funding - Gilead Sciences (Inst) |
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen |
| |
|
Stock and Other Ownership Interests - 3rdEyeBio; Emerging Markets Cancer Ignition Fund; New Equilibrium Biosciences; Novilla; Phoenix Molecular Designs; Sengine precision medicine; Tahoma Therapeutics |
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Hologic; Puma Biotechnology; Seagen/Pfizer; Stemline Therapeutics |
Speakers' Bureau - Hologic; Puma Biotechnology; Seagen; Stemline Therapeutics |
Research Funding - Agendia (Inst); Illumina; Tizona Therapeutics, Inc. |
Travel, Accommodations, Expenses - Genentech/Roche; Puma Biotechnology; Seagen |
| |
|
|
Research Funding - Abbvie (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Agendia |
Other Relationship - Agendia |
| |
|
Leadership - Evolent (I); Progyny (I) |
Stock and Other Ownership Interests - Evolent (I) |
Consulting or Advisory Role - GE Healthcare; Gilead Sciences; Novartis; Pfizer; Sanofi |
Research Funding - Pfizer (Inst); Sanofi/Aventis (Inst); Tolmar (Inst); Veru; Zeno Pharmaceuticals (Inst); Zionexa (Inst); Zymeworks (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Blue Cross Blue Shield Association |
Research Funding - Moderna Therapeutics (Inst) |
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association |
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
Stock and Other Ownership Interests - Agendia |
Consulting or Advisory Role - Celanese; Private Health; Quantum Health |
Research Funding - Agendia |
Travel, Accommodations, Expenses - Agendia |
| |
|
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru |
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru |
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen |
Travel, Accommodations, Expenses - Agendia; Aptitude Health; AstraZeneca; Daiichi Sankyo; DAVA Oncology; Eisai; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Roche; Seagen |